208 related articles for article (PubMed ID: 32584461)
1. Patient Characteristics and Outcomes of Nonmetastatic Breast Cancer in Haiti: Results from a Retrospective Cohort.
Fadelu T; Damuse R; Lormil J; Pecan E; Dubuisson C; Pierre V; Rebbeck T; Shulman LN
Oncologist; 2020 Sep; 25(9):e1372-e1381. PubMed ID: 32584461
[TBL] [Abstract][Full Text] [Related]
2. Body Mass Index, Chemotherapy-Related Weight Changes, and Disease-Free Survival in Haitian Women With Nonmetastatic Breast Cancer.
Fadelu T; Damuse R; Lormil J; Pecan E; Greenberg L; Dubuisson C; Pierre V; Triedman SA; Shulman LN; Rebbeck TR
JCO Glob Oncol; 2020 Oct; 6():1656-1665. PubMed ID: 33151773
[TBL] [Abstract][Full Text] [Related]
3. Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer.
Fadelu TA; Erfani P; Lormil J; Damuse R; Pierre V; Slater S; Triedman SA; Shulman LN; Rebbeck TR
Breast Cancer Res Treat; 2022 Jun; 193(3):625-635. PubMed ID: 35420316
[TBL] [Abstract][Full Text] [Related]
4. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
5. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.
Christopherson K; Lei X; Barcenas C; Buchholz TA; Garg N; Hoffman KE; Kuerer HM; Mittendorf E; Perkins G; Shaitelman SF; Smith GL; Stauder M; Strom EA; Tereffe W; Woodward WA; Smith BD
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):574-581. PubMed ID: 30851348
[TBL] [Abstract][Full Text] [Related]
7. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
8. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.
Buchholz TA; Hill BS; Tucker SL; Frye DK; Kuerer HM; Buzdar AU; McNeese MD; Singletary SE; Ueno NT; Pusztai L; Valero V; Hortobagyi GN
Cancer J; 2001; 7(5):413-20. PubMed ID: 11693900
[TBL] [Abstract][Full Text] [Related]
9. Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer.
Roy-Luzarraga M; Abdel-Fatah T; Reynolds LE; Clear A; Taylor JG; Gribben JG; Chan S; Jones L; Hodivala-Dilke K
JAMA Netw Open; 2020 Oct; 3(10):e2019304. PubMed ID: 33107920
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments.
Yu JI; Park W; Choi DH; Huh SJ; Nam SJ; Kim SW; Lee JE; Kil WH; Im YH; Ahn JS; Park YH; Cho EY
Clin Breast Cancer; 2015 Dec; 15(6):512-8. PubMed ID: 26188791
[TBL] [Abstract][Full Text] [Related]
12. [Local recurrence based on size after conservative surgery in breast cancer stage T1-T2. A population-based study].
Martínez-Ramos D; Fortea-Sanchis C; Escrig-Sos J; Prats-de Puig M; Queralt-Martín R; Salvador-Sanchis JL
Cir Cir; 2014; 82(3):252-61. PubMed ID: 25238466
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana.
Ayettey Anie H; Yarney J; Sanuade O; Awasthi S; Ndanu TA; Parekh AD; Aidoo C; Dadzie MA; Vanderpuye V; Yamoah K
JCO Glob Oncol; 2021 Jun; 7():965-975. PubMed ID: 34156868
[TBL] [Abstract][Full Text] [Related]
14. Presentation, Treatment, and Outcomes of Haitian Women With Breast Cancer in Miami and Haiti: Disparities in Breast Cancer-A Retrospective Cohort Study.
Gomez A; DeGennaro V; George SHL; Reis IM; Santamaria E; Westin GF; Gabriel D; Hurley J
J Glob Oncol; 2017 Aug; 3(4):389-399. PubMed ID: 28831447
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer.
Loap P; Nicaise B; Laki F; Loirat D; Pierga JY; Fourquet A; Kirova Y
Strahlenther Onkol; 2023 Jan; 199(1):30-37. PubMed ID: 35648170
[TBL] [Abstract][Full Text] [Related]
16. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
17. Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study.
Abdel-Rahman O; Kumar A; Kennecke HF; Speers CH; Cheung WY
Clin Colorectal Cancer; 2018 Mar; 17(1):e21-e28. PubMed ID: 28709877
[TBL] [Abstract][Full Text] [Related]
18. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
Chen J; Wu X; Christos PJ; Formenti S; Nagar H
Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and outcomes in older women with early breast cancer: a population-based cohort study in China.
Liu X; Zheng D; Wu Y; Luo C; Fan Y; Zhong X; Zheng H
BMC Cancer; 2021 Mar; 21(1):226. PubMed ID: 33673816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
